The Department of Health and Human Services (HHS) announced on August 5, 2025, that it will wind down all mRNA vaccine development projects funded by the Biomedical Advanced Research and Development Authority (BARDA). In a single stroke, Secretary Robert F. Kennedy Jr. ended 22 active programs—totaling roughly $500 million in taxpayer support—and barred any new mRNA initiatives from launching under BARDA’s umbrella.
Kennedy justified the decision by pointing to data showing that mRNA vaccines have delivered limited protection against upper-respiratory viruses such as influenza and SARS-CoV-2 once they mutate. “We reviewed the science, listened to the experts and acted,” he stated, pledging to redirect resources toward “safer, broader vaccine platforms” that retain effectiveness even as pathogens evolve.
Among the canceled efforts was Moderna’s H5N1 bird-flu candidate, previously cut in May, as well as contracts with Emory University, Tiba Biotech, Luminary Labs, ModeX and Seqirus. Pending completion are nearly finished programs—like Arcturus’s bird-flu vaccine and Amplitude Therapeutics’s RNA-amplification platform—which will conclude under existing agreements. In parallel, BARDA Ventures was instructed to cease all new equity investments in mRNA technologies.
In place of mRNA, HHS plans to bolster development of whole-virus vaccines and an NIH-backed “Generation Gold Standard” universal-vaccine platform. A spokesperson emphasized that long-term safety data for mRNA vaccines remain limited, despite extensive evidence of their rapid design, robust antibody response and favorable safety profile dating back to the COVID-19 rollout.
The move sparked sharp criticism from public-health experts. Dr. Paul Offit of Children’s Hospital of Philadelphia warned that discarding mRNA capabilities “puts this country at unnecessary risk,” while epidemiologist Dr. Michael Osterholm called it “one of the worst decisions I’ve seen in 50 years of public-health preparedness.” They argued that mRNA’s flexible, fast-manufacturing processes are irreplaceable for responding to emerging pandemics and rapidly mutating viruses.
As the world braces for future respiratory threats, HHS’s pivot marks a bold recalibration of U.S. vaccine strategy—one that replaces cutting-edge nucleic-acid platforms with more traditional and yet-to-be-proven approaches.